ESSA Pharma Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Selling, General & Admin	10.81	12.54	12.88	11.37	5.46	5.93	5.14	5.64	5.26	1.07
Research & Development	21.32	24.42	24.26	12.15	6.7	4.87	5.73	13.06	4.98	0.67
Operating Expenses	32.13	36.96	37.14	23.52	12.15	10.8	10.87	18.7	10.23	1.74
Operating Income	-32.13	-36.96	-37.14	-23.52	-12.15	-10.8	-10.87	-18.7	-10.23	-1.74
Interest Expense / Income	0.01	0.01	0.02	0.62	0.6	0.91	0.78	0.94	0.09	0.09
Other Expense / Income	-5.56	-1.76	-0.33	-0.4	-0.04	-0.11	-7.27	-6.65	-0.65	-0
Pretax Income	-26.58	-35.22	-36.84	-23.73	-12.72	-11.6	-4.38	-12.99	-9.68	-1.82
Income Tax	0	-0.11	-0.03	-0.29	0.04	0.03	0.12	0.15	0	0
Net Income	-26.58	-35.1	-36.81	-23.45	-12.76	-11.63	-4.5	-13.14	-9.68	-1.82
Shares Outstanding (Basic)	44	44	38	22	8	5	1	1	1	1
Shares Outstanding (Diluted)	44	44	38	22	8	5	1	1	1	1
Shares Change	0.12%	14.44%	71.45%	166.13%	84.68%	213.86%	8.16%	46.59%	16.99%	-
EPS (Basic)	-0.60	-0.80	-0.96	-1.04	-1.51	-2.55	-3.09	-9.77	-10.60	-2.40
EPS (Diluted)	-0.60	-0.80	-0.96	-1.04	-1.51	-2.55	-3.09	-9.77	-10.60	-2.40
Free Cash Flow	-19.78	-28	-25.42	-16.98	-12.25	-10.22	-17.35	-15.31	-13.51	-2.08
Free Cash Flow Per Share	-0.45	-0.64	-0.66	-0.76	-1.45	-2.24	-11.93	-11.38	-14.73	-2.65
EBITDA	-26.46	-35.08	-36.71	-23.01	-12.12	-10.66	-3.55	-11.98	-9.54	-1.71
Depreciation & Amortization	0.12	0.12	0.11	0.11	0	0.03	0.05	0.07	0.04	0.02
EBIT	-26.57	-35.2	-36.82	-23.12	-12.12	-10.69	-3.6	-12.05	-9.58	-1.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).